T. Rowe Price Associates
OPTN

T. Rowe Price Associates’s OptiNose OPTN Stock Holding History

T. Rowe Price Associates’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,243
Closed -$28K – 2996
2024
Q1 		$28K Buy
1,243
+76
+7% +$1.69K ﹤0.01% 2918
2023
Q4 		$23K Buy
1,167
+174
+18% +$3.18K ﹤0.01% 2866
2023
Q3 		$19K Sell
993
-13,871
-93% -$250K ﹤0.01% 2852
2023
Q2 		$275K Buy
+14,864
New +$352K ﹤0.01% 2404

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates's OPTN Position: Q2 2024 in Review

T. Rowe Price Associates sold out of OptiNose (OPTN) in Q2 2024, closing a stake of 1,243 shares — an estimated $28K sold.

T. Rowe Price Associates first reported a position in OPTN in Q2 2023 and held it in 4 quarters. The position peaked at $275K in Q2 2023. 84 funds tracked by Wall St. Rank hold OPTN as of Q2 2024.

  • T. Rowe Price Associates reported no remaining OptiNose position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,243 OptiNose shares in Q2 2024, an estimated $28K.
  • T. Rowe Price Associates first reported a position in OptiNose in Q2 2023 and held it in 4 quarters.
  • T. Rowe Price Associates's OptiNose position peaked at $275K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held OptiNose as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.